Introduction
©1998 International Medical Press 0956-3202/98/$17.00 This is due to poor phosphorylation of 1 in HCMVinfected cells Thus if the first phosphorylation step were rate-limiting, then the successful intracellular delivery of the 5′-monophosphate of 1 using our phosphate delivery technology could confer anti-HCMV activity on this compound. Thus, the use of blocked phosphate esters of 1 may have the potential to generate a more broad spectrum anti-herpesvirus agent. Herein we describe the synthesis and antiviral evaluation of 5′phosphate esters of 1. Furthermore, in an effort to rationalize the biological action noted, we describe the study of the esterase lability of one of the key target compounds.
Materials and Methods: Chemistry
1 H, 13 C and 31 P NMR spectra were recorded using Jeol FX90, Jeol JMN GX270, Bruker DPX300, Bruker AC300 and Bruker AM360 fourier transform spectrometers. All 1 H and 13 C NMR chemical shifts (δ) are quoted in p.p.m. downfield from tetramethylsilane. All 31 P chemical shifts are quoted in p.p.m. using H 3 PO 4 as the external reference. Mass spectra were recorded using VG 70-250, Kratos MS50 RFTC and Kratos Concept 1S mass spectrometers and the modes of ionization were electron impact (EI), electrospray (ES) and fast atom bombardment (FAB) . Microanalysis was performed using the Carlo Erba CE1106 C, H, N Analyser. All analytical high-performance liquid chromatography (HPLC) experiments were carried out using an ACS 350/04 system with an ACS 750/12 ultraviolet detector set at 254 nm on a techsphere ODS 5 (250×4.6 mm) reverse-phase column. Mobile phase A was water, B was acetonitrile, gradient conditions were 82% A at 0 min, 20% A at 30 min, 20% A at 45 min, with a flow rate of 1 ml/min. All retention times are quoted in min. IR spectra were obtained with a Perkin-Elmer 1600 fourier transform spectrometer. Polygram SIL G/UV/254 precoated plates were used for thin layer chromatography. Merck silica gel (40-60 µm) was used for column chromatography. Dichloromethane, diethyl ether, triethylamine and pyridine were dried over calcium hydride and distilled at atmospheric pressure. Dichloromethane and diethyl ether were further dried using 4 Å molecular sieves. Tetrahydrofuran was dried over sodium benzophenone and distilled under nitrogen. All other solvents and reagents were used as supplied.
882C-5′-diethyl phosphate (2a)
Diethyl phosphorochloridate (0.193 g, 1.1 mmol, 1.1 equiv.) was added to a solution of 882C (0.282 g, 1.0 mmol) in pyridine (25 ml) at room temperature. Further diethyl phosphorochloridate was added after 29 h (0.5 equiv., 0.085 g, 0.5 mmol). The reaction was allowed to proceed for a further 15 h and then the solvent was removed (in vacuo, azeotroping with toluene, 2×25 ml 3416, 1704, 1692, 1462, 1285, 1285, 1250, 1028. 882C-5′-bis-(2,2,2-trichloroethyl) phosphate (2b) This was prepared by a procedure entirely analogous to that outlined for 2a above, except that stirring was continued for 16 h in total, and the chromatographic eluant used was 10% MeOH, 90% DCM. 65% yield, m.p. 194°C. 1 H NMR (AM360) (CD 3 OD) δ 7.82 (1H, s, H-6), 6.16 (1H, d, J 3.7 4329, 4256, 2725, 1694, 1669, 1303, 1164, 1079, 964 
882C-5′-didodecyl phosphate (2d)
This was prepared by a procedure entirely analogous to that outlined for 2a above, except that stirring was continued for 20 h in total, and the chromatographic eluant used was 8% MeOH, 92% DCM. 37% yield, m.p. 100-102°C. 1 4327, 4255, 3456, 1703, 1636, 1613, 1304, 1262, 1138, 1042, 776. 882C-5′-phosphate esters as potential antiviral agents
882C-5′-dihexadecyl phosphate (2e)
This was prepared by a procedure entirely analogous to that outlined for 2a above, except that 3 M equivalents of the appropriate phosphorochloridate were used, and stirring was continued for 23 h in total. The solvent was removed (azeotroping with toluene, 3×20 ml) to afford an oil. The oil was dissolved in dichloromethane (20 ml), washed with 2 M hydrochloric acid (20 ml), neutralized with saturated sodium hydrogen carbonate solution (20 ml) and dried (MgSO 4 ). The dry organic extract was filtered and concentrated (reduced pressure) to afford a pink solid. The desired product was isolated using column chromatography (eluant 5% MeOH, 95% DCM) as a glass-solid (0.191 g, 28% yield 2923, 2853, 1704, 1680, 1631, 1468, 1285, 1024, 873, 809, 736. 
882C-5′-diphenyl phosphate (2f)
This was prepared by a procedure entirely analogous to that outlined for 2a above, except that the reaction was started at -50°C, and then allowed to warm to ambient temperature over 18 h. The isolation procedure was otherwise as outlined for 2a, with a chromatographic eluant of 5% MeOH, 95% DCM. 74% yield. 1 2923, 2828, 2361, 1722, 1674, 1450, 1343, 1207, 1097, 973. 882C-5′-(2,6-dimethylphenyl) phosphate (2g) This was prepared by a procedure entirely analogous to that outlined for 2a above, except that 1.8 M equivalents of phosphorochloridate were used and stirring was continued for 23 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 24% yield. 1 H NMR (AC300) (CDCl 3 ) δ 10.42 (1H, s, NH), 7.63 (1H, s, H-6), 7.09-6.80 (8H, m, 8×Ph-H), 6.01 (1H, d, J 3.3 Hz, H-1′), 4.49-4.38 (7H, m, H-2′, H-3′, H-4′, 2×H-5′, 2×OH), 2.34 (6H, d, J PH 8.6 Hz, 2×Ph-Me), 1.86 (3H, s, C ≡ C-Me); LR FAB MS (VG) (Ar, MNOBA matrix) m/e 1141 (M 2 H + , 2%), 571 (MH + , 34%), 421 (MH + -base, 100%), 307 ((2,6-MePhO) 2 P(O)OH 2 +, 72%), 265 (MH + -306), 151 (baseH + , 21%), 122 (2,6-MePh + , 29%); HPLC retention time (min) 39.72; IR (reciprocal cm) 4328, 4257, 3360, 3168, 2726, 2247, 1927, 1856, 1678, 1621, 1284, 1186, 1154, 1092, 1025, 964, 769. 
882C-5′-bis-(2-chlorophenyl) phosphate (2h)
This was prepared by a procedure entirely analogous to that outlined for 2e above, except that 2 M equivalents of phosphorochloridate were used and stirring was continued for 15 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 24% yield. 1 
882C-5′-bis-(3-chlorophenyl) phosphate (2i)
This was prepared by a procedure entirely analogous to that outlined for 2a above, except that 1.5 M equivalents of phosphorochloridate were used and stirring was continued for 18 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 32% yield. 1 H NMR (AC300) (CDCl 3 ) δ 10.51 (1H, s, NH), 7.78 (1H, s, H-6), 7.40-7.08 (8H, m, 8×Ph-H), 6.18 (1H, d, J 3.7 Hz, H-1′), 4.89 (1H, s, OH), 4.68-4.39 (4H, m, H-2′, H-3′, H-4′, OH), 4.37-4.17 (2H, d, J 5.9 Hz, 2×H-5′), 1.85 (3H, s, C ≡ C-Me); LR FAB MS (VG) (Ar, MNOBA matrix) m/e 585 (MH + , 37 Cl, 2%), 583 (MH + , 4%), 435 (MH + -base, 37 Cl, 4%), 433 (MH + -base, 6%), 321 ((3-Cl-PhO) 2 PO 2 H 2 + , 37 Cl, 5%), 319 ((3-Cl-PhO) 2 PO 2 H 2 + , 8%), 265 (MH + -318, 2%), 151 (baseH + , 100%), 136 (baseH + -Me, 69%), 77 (Ph + , 18%); microanalysis C 24 H 21 Cl 2 N 2 O 9 P•(H 2 O) 0.4 requires C 48.86%, H 3.68%, N 4.75%; obtained C 48.86%, H 3.63%, N 4.62%; HPLC retention time (min) 35.00; IR (reciprocal cm) 3396, 3071, 2250, 1703, 1621, 1580, 1471, 1430, 1285, 1197, 1129, 1090, 1032, 1006, 971, 869, 831, 780, 738. 882C-5′-bis-(4-chlorophenyl) phosphate (2j) This was prepared by a procedure entirely analogous to that outlined for 2e above, except that 1.2 M equivalents of phosphorochloridate were used and stirring was continued for 15 h in total. The chromatographic eluant used was 10% MeOH, 90% DCM. 41% yield. 1 3400, 3054, 2986, 1709, 1700, 1679, 1486, 1423, 1265, 1195, 1093, 1034, 1014, 966, 896, 739. 882C-5′-bis-(4-fluorophenyl) phosphate (2k) This was prepared by a procedure entirely analogous to that outlined for 2e above, except that 1.6 M equivalents of phosphorochloridate were used and stirring was continued for 17 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 12% yield. 1 3397, 2361, 1698, 1623, 1501, 1468, 1285, 1200, 1178, 1150, 1092, 1034, 969, 840. 882C-5′-bis-(4-methoxyphenyl) phosphate (2l) This was prepared by a procedure entirely analogous to that outlined for 2e above, except that 2.6 M equivalents of phosphorochloridate were used and stirring was continued for 26 h in total. The chromatographic eluant used was 10% MeOH, 90% DCM. 20% yield. 1 3054, 1692, 1504, 1467, 1266, 1211, 1180, 1034, 970, 834, 745. 
882C-5′-(ethyl phenyl) phosphate (3a)
This was prepared by a procedure entirely analogous to that outlined for 2a above, except that 1.2 M equivalents of phosphorochloridate were used and stirring was continued for 20 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 56% yield. 1 3368, 3056, 2836, 2362, 2251, 1698, 1623, 1593, 1490, 1487, 1348, 1265, 1209, 1030, 955, 909, 873, 810, 739, 604. 882C-5′-(phenyl 2,2,2-trichloroethyl) phosphate (3b) This was prepared by a procedure entirely analogous to that outlined for (2a) 3394, 3055, 2987, 2832, 2306, 1702, 1622, 1592, 1490, 1488, 1422, 1265, 1206, 1111, 1026, 962, 898, 896. 882C-5′-(4-nitrophenyl phenyl) phosphate (3c) This was prepared by a procedure entirely analogous to that outlined for 2a above, except that 1.1 M equivalents of phosphorochloridate were used and stirring was continued for 19 h in total. The chromatographic eluant used was 10% MeOH, 90% DCM. 20% yield. 1 H NMR (AC300) (CD 3 OD) δ 8. m, 4330, 4257, 2725, 1679, 1589, 1301, 1157, 1023, 964. 882C-5′-(n-propylamino phenyl) phosphate (4a) N-Propylamino phenyl phosphorochloridate (1.3 M tetrahydrofuran solution, 1.4 ml, 1.8 mmol, 0.42 g, 1.2 equiv.) and N-methylimidazole (0.6 ml, 0.62 g, 7.5 mmol, 4.8 equiv.) were added to a suspension of 882C (0.438 g, 1.6 mmol) in tetrahydrofuran (10 ml). Further N-propylamino phenyl phosphorochloridate (1.3 M tetrahydrofuran solution, 3.5 ml, 4.5 mmol, 1.05 g, 3.0 equiv.) was added after 21 h and the reaction mixture was allowed to stir for a further 17 h. The solvent was removed (in vacuo) to afford an oil. The oil was dissolved in dichloromethane (20 ml) and the resulting solution was washed with saturated CuSO 4 solution (10 ml) and water (10 ml). The desired product (0.280 g, 37% yield) and 882C (0.108 g, 25% yield) were separated using column chromatography (eluants 10% MeOH, 90% DCM 4196, 3401, 3054, 2986, 2307, 1697, 1624, 1593, 1491, 1463, 1421, 1286, 1211, 1025, 946, 896. 
882C-5′-(dodecylamino phenyl) phosphate (4b)
This was prepared by a procedure entirely analogous to that outlined for 4a above, except that 2.4 M equivalents of phosphorochloridate were used and stirring was continued for 23 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 12% yield. 1 H NMR (AC300) (CDCl 3 ) δ 7.76 (1H, s, H-6), 7.37-7.02 (5H, m, 5×Ph-H), 6.14 (1H, s, H-1′ 3370, 2930, 2853, 2306, 1706, 1623, 1491, 1466, 1279, 1128, 1075, 1046, 930, 811, 740, 691. 
882C-5′-(L-methoxyalaninyl phenyl) phosphate (4c)
This was prepared by a procedure entirely analogous to that outlined for 4a above, except that 1.5 M equivalents of phosphorochloridate were used and stirring was continued for 24 h in total. The chromatographic eluant used was 10% MeOH, 90% DCM. 22% yield. 1 H NMR (AC300) (CDCl 3 ) δ 7.78, 7.74 (1H, s, H-6), 7.39-7.10 (5H, m, 5×Ph-H), 6.12, 6.10 (1H, d, J 4. 
882C-5′-(L-methoxyvalinyl phenyl) phosphate (4d)
This was prepared by a procedure entirely analogous to that outlined for 4a above, except that 2.2 M equivalents of phosphorochloridate were used and stirring was continued for 20 h in total. The chromatographic eluant used was 5% MeOH, 95% DCM. 9% yield (5 : 6 mixture of diastereoisomers; * denotes major diastereoisomer 4196, 3945, 3384, 3054, 2986, 2305, 1692, 1623, 1592, 1491, 1462, 1423, 1265, 1210, 1147, 1025, 942, 896. 882C 5′-triphosphate 882C (1) (0.3 g, 1.1 mmol) was dissolved in trimethyl phosphate (7 ml) and cooled to 0°C. Phosphorus oxychloride (0.24 ml, 2.7 mmol) was added, stirred for 4 h, then the reaction was stopped by adding 0.3 M triethylammonium bicarbonate (25 ml). The solution pH was adjusted to 8 with ammonium hydroxide then diluted with water to a conductivity of 4000 mmho. This sample was applied to a DEAE Sephadex A25 (Pharmacia) column and eluted with a gradient of 50-500 mM ammonium bicarbonate. Fractions containing the 882C 5′-monophosphate were combined, dried in vacuo, redissolved in water then dried again to yield 0.49 g of the ammonium salt of 882C 5′monophosphate. The ammonium salt was converted to the triethylammonium salt by addition and evaporation of 0.1 M triethylammonium bicarbonate (2×15 ml) to yield 0.5 g of 882C 5′-monophosphate.
The compound gave a single spot (Rf 0.19) by TLC on cellulose developed in n-PrOH/15 M NH 4 OH/H 2 O (6 : 3 : 1) and gave a single peak by HPLC on Whatman Partisil 10 SAX eluted with a gradient of 0.01-1 M ammonium phosphate pH 5.5, at A 280 . 882C 5′-monophosphate triethylammonium salt (0.9 mmol) was dissolved in hexamethyl phosphoramide (10 ml) and 1,1′-carbonyldiimidazole (0.75 g) was added and stirred for 1 h at room temperature. Methanol (0.3 ml) was added and stirred for 1 h. Tributylammonium pyrophosphate (2.1 g) was added and stirred overnight at room temperature. The reaction mixture was diluted with water to a conductivity of 3000 mmho and was applied to a DEAE Sephadex A25 (Pharmacia) column that was eluted with a gradient of 50-800 mM ammonium bicarbonate. The fractions containing the 882C triphosphate were combined, dried in vacuo, redissolved in water then dried again to yield the ammonium salt of the 882C triphosphate. The compound gave a single spot (Rf 0.10) by TLC cellulose developed in n-PrOH : 15 M NH 4 OH : H 2 O (6 : 3 : 1) and was 99% pure by HPLC on Whatman Partisil 10 SAX eluted with a gradient of 0.01-1 M ammonium phosphate pH 5.5. An aliquot of 882C 5′-triphosphate was treated with alkaline phosphatase (calf intestine, Boehringer Mannheim) or phosphodiesterase I (snake venom, Pharmacia). Alkaline phosphatase totally cleaved 882C 5′-triphosphate to nucleoside. Phosphodiesterase I totally cleaved 882C 5′-triphosphate to 882C monophosphate. Chromatography was performed on thin layer cellulose developed in n-PrOH : 15 M NH 4 OH : H 2 O (6 : 3 : 1).
Materials and Methods: Enzymology
Pig liver esterase (EC 3.1.1.1; Sigma) (40 mg, approximately 15 units/mg) was added in a single portion to a solution of test compound (4c or 6; 5 mg) in 0.05 M Trizma buffer pH 7.6 made up in D 2 O (1 ml) containing acetone (0.1 ml). The solution was mixed gently and incubated in a 5 mm diameter NMR tube at 37°C. After 19 h, each solution was examined by 31 P NMR and the product mixture determined by comparison with authentic samples and NMR integration giving approximate percentages. Incubation of 6: 31 P NMR (D 2 O/acetone) δ 5.55 (6, 2×s, 79%), 8.04 (7, 21%). Incubation of 4c: 31 P NMR (D 2 O/acetone) δ 5.50 (4c, 2×s, 54%), 8.43 (8, 46%). The samples were then filtered through celite and the filtrates examined by low resolution negative ion ES mass spectrometry. Incubation of 6: m/e 374 (7, M-H, 100%); incubation of 4c: m/e 432 (8, M-H, 100%).
Materials and Methods: Virology
The ability of compounds to inhibit the growth of Vero cells was assessed in Eagle's MEM with 10% calf serum. Compounds were prepared in growth medium to appropriate concentrations by a twofold dilution series and assayed using a 96-well microtitre format. Compound was added to wells at the time of addition of cells. Rapidly growing cells, freshly harvested by trypsinization were diluted in medium to give 10 000 cells/well in a final volume of 200 ml. Replicate plates were incubated at 37°C in an atmosphere containing 5% CO 2 for 48 h. At the end of the incubation period, viable cells were determined using uptake of the tetrazolium dye 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT). The concentration of compound inhibiting cell replication by 50% was termed the CC 50 . Compounds were evaluated for antiviral activity by plaque reduction. Confluent monolayers of cells in 35 mm Petri dishes were infected with 50-150 p.f.u. of virus suspension. Virus was allowed to adsorb for 1 h at 37°C prior to the addition of inhibitor in the culture medium (Dulbecco's modified Eagle's medium, containing 5% fetal bovine serum plus antibiotics). The cell monolayer was then overlaid with nutrient agarose containing carboxymethylcellulose, 0.1 mg/ml trypsin, 100 mg/ml DEAE-dextran and the test compound at an 882C-5′-phosphate esters as potential antiviral agents appropriate concentration. After an incubation period at 37°C the cells were fixed with formalin and stained with methyl violet to visualize the plaques. The plaques of dead cells resulting from viral growth were counted. Plaque counts, expressed as a percentage of the infected control (no compound) were determined at each compound concentration. The mean was plotted against the log 10 of the compound concentration to yield a dose-response curve from which the 50% inhibitory concentration (EC 50 ) was determined. The viral strains and incubation times were: HCMV, AD169, 6 days; HSV-2, SC16, 2 days; VZV, G-31, 2 days; HIV-1, HXB2, 4 days and influenza virus, A/Sweden/3/50 (H1N1), 2 days.
Materials and Methods: Polymerase Assay

DNA polymerase preparations
HSV-1 and HSV-2 DNA polymerases were extracted from virus-infected HEp-2 cells and purified by DEAE-cellulose, phosphocellulose (Whatman, P11) and DNA cellulose (Pharmacia) chromatography, essentially as described by Powell & Purifoy (1977) . VZV DNA polymerase was co-expressed with its accessory protein (gene 16) in insect cells using a recombinant baculovirus expression system (Ertl et al., 1991; Ohmstede & S Short, Burroughs Wellcome, Research Triangle Park, N.C., USA; personal communication). The accessory protein was expressed with the three amino acid motif (EEF) at the C terminus, which forms the recognition site for the monoclonal antibody YL1/2 (Stammers et al., 1991) . This was used for immunoaffinity purification of the complex similarly to that described by Ertl & Powell (1992) .
Assay for DNA polymerase activity
All DNA polymerase assays were performed at 37°C. For the HSV-1 and HSV-2 polymerases, the assay mixes contained 50 mM Tris-HCI pH 7.5, 5 mM MgCl 2 , 5 mM DTT, 100 mM KCl, 100 mg/ml activated calf thymus DNA, 50 µM dATP, dCTP and dTTP and a varied amount of [ 3 H]dGTP (2 Ci/mmol). The VZV polymerase/gene 16 assay mix was similar except that the assay had a pH of 8.0 and included 200 mM KCl. The incorporation of [ 3 H]dGTP into DNA was followed by binding of the polymerized DNA onto DEAE-cellulose paper and scintillation counting (Ertl & Powell, 1992) . Kinetic data was analysed by non-linear least-squares methods to determine IC 50 and K i values using the program GraFit (RJ Leatherbarrow, Erithicus Software, Imperial College, London, UK). 
Compound 1 and acyclovir are included as positive biological controls. The cell lines in which the EC 50 assays were conducted were: HCMV, MRC-5 cells; HSV-2, Vero cells; VZV, MRC-5 cells; influenza A virus, MDCK cells; HIV-1, HeLa cells. CC 50 assays were performed in Vero cells. (T) indicates cytotoxicity was observed at or slightly above the antiviral concentration noted. ND, Not determined.
Results
A series of phosphate esters of compound 1 were synthesized using established phosphorochloridate methodology (McGuigan et al., 1990) (Fig. 1) . Each of the compounds was characterized by a range of spectroscopic and analytical methods. In particular, full high-field 13 C and 31 P NMR (supplementary data, available on request from the Editorin-Chief ), proton NMR, mass spectrometry, microanalysis and HPLC data confirmed the structure and purity of these compounds. Phosphorylation of the primary 5′-OH by the relatively hindered phosphorochloridates/phosphoramidochloridates is sterically favoured. However, phosphorylation of the other hydroxy groups can occur and was observed by TLC. The addition of the phosphorylating reagent at -50°C increased the yield for the preparation of 5′-diphenyl phosphate (2f) from 35% to 74%, since only phosphorylation of the 5′-OH has a significant rate at this temperature, and it may have been possible to enhance the yields of other phosphorylation reactions of 1 by using the low temperature addition method.
Each of the phosphate esters (2a-l, 3a-c and 4a-d) were evaluated for their inhibition of HCMV, HSV-2, VZV, influenza A virus and HIV-1; results are shown in Table 1 . Compound 1 and acyclovir were included as positive biological controls.
Discussion
As noted in Table 1 , all of the phosphate esters were inactive against the range of viruses at non-cytotoxic concentrations, except the 5′-(4-nitrophenyl phenyl) phosphate (3c), which did appear to inhibit influenza A virus (EC 50 2.3 µM). This compound displayed a selectivity index (SI) of 48 under the assay conditions for this virus. The biological mode of action of 3c against influenza A virus is not presently understood. However, it is known that the 5′-triphosphate of 1 does not inhibit influenza A virus RNA polymerase at 100 µM (M Ellis, Glaxo Wellcome, Stevenage, UK, personal communication) and therefore another, less apparent, mode of action must be considered. It is interesting to note, however, that ostensibly rather similar structures to 3c, notably 2f, were found to be entirely inactive against the virus, indicating a rather specific mode of action for 3c. The high leaving group propensity of the nitrophenyl group in 3c might indicate a mode of action involving hydrolysis of this moiety to give the appropriate phenyl phosphate diester, and this possibility is currently under investigation. However, we did note that the by-product from this hydrolysis, p-nitrophenol, is not active against influenza A virus at 100 µM.
Neither 3c, nor indeed any of the phosphate esters of 1, demonstrated any discernable anti-VZV activity ( Table 1) . The generation of 1 or the 5′-monophosphate thereof from any of the 5′-phosphate esters in the VZV assay would ultimately have resulted in the formation of the 5′-triphosphate of 1 and activity against this virus. Thus, the inactivity of the wide range of phosphate derivatives herein described against VZV does suggest that neither 1 nor its 5′-monophosphate were formed from the protected phosphates in sufficient quantity under the assay conditions. The failure to generate the 5′-monophosphate of 1 in the assay contrasts strongly with the successful generation of the monophosphate from the corresponding AZT-and d4T-5′-phosphoramidate esters 5 and 6. These results are consistent with the suggestion that the cleavage of the ester groups from phosphorus to generate the monophosphate is accomplished by enzymes rather than chemical hydrolysis . A notable difference between the anti-HIV evaluation of the corresponding 5′-phosphate esters of AZT and d4T and the present antiviral studies on the phosphates of 1 regards the cell lines used. It is possible that the requisite hydrolytic enzymes are present in CEM and MT4 cells (used in the anti-HIV evaluation), but are not present in Vero or MRC-5 cells (used in the present studies).
In order to probe further this issue, we set up a pig liver esterase assay as a guide to the relative esterase lability of the phosphate esters of 1. Indeed, we have recently noted the predictive power of such an assay; certain β-amino acid analogues of 6 were noted to be inactive against HIV, and were found not to be processed by esterase to give 7, while α-amino acid compounds, such as 6, were efficiently processed by esterase to 7 and were potent antivirals. Thus, we suggested esterase-mediated conversion to the free amino acyl phosphoramidate to be a necessary condition for antiviral action (McGuigan et al., 1998) . Since the phenyl methoxyalaninyl phosphate of d4T (6) has proven to be a particularly efficient phosphate delivery motif (McGuigan et al., 1997) , we compared the rate of esterasemediated hydrolysis of 6 to that of the corresponding 882C phosphoramidate (4c). It was notable that under the conditions of the assay, 4c was in fact hydrolysed to a greater extent than 6. Thus after 19 h at 37°C, compound 6 displayed 20% degradation to the suggested key metabolic intermediate, d4T alaninyl phosphate (7) . In contrast, 4c generated 46% of the new metabolite 882C 5′-(alaninyl phosphate) (8) under these conditions. These metabolites were characterized in situ by high-field 31 P NMR, mass spectrometry and (in the case of 7) chromatographic comparison with authentic samples .
Thus, it is apparent that the differences in the nucleoside structures of 4c and 6 do not lead to a reduction in the rate of esterase-mediated metabolism of 6 to its hydrolytic 882C-5′-phosphate esters as potential antiviral agents intermediates; indeed the rate of esterase-mediated metabolism is faster for 4c than 6. Therefore, the poor antiviral action of the 882C phosphoramidate series may be attributed to low levels of appropriate hydrolytic esterases in the cell lines used for the evaluation of inhibition of HCMV and VZV, or to poor onward processing of 8 in comparison to 7.
To pursue further this hypothesis, we prepared the 5′triphosphate of 1 (882C-TP) to test directly against VZV-, HSV-2-and HCMV-derived DNA polymerases. Indeed, we note that, although 882C (1) is a specific anti-VZV agent, the K i of 882C-TP against VZV DNA polymerase (160±10 nM) was rather similar to its K i values versus HSV-2 DNA polymerase (100±5 nM) and HCMV DNA polymerase (600±50 nM). This further supports the suggestion that the narrow spectrum of antiviral action of 882C relates to poor phosphorylation in HCMV-infected cells in comparison to VZV-infected cells. Furthermore, it adds support to the suggestion that alternative phosphate delivery motifs may be successful in broadening the antiviral spectrum of action of 1, if phosphate delivery could be achieved and therapeutic levels of 882C-triphosphate generated. Such detailed investigations are currently underway in our laboratories, and interest in this is heightened by the knowledge that esterase-mediated hydrolysis is not impeded for the 882C compounds in comparison to earlier d4T nucleosides.
In conclusion, the combined esterase and polymerase data that we herein disclose implies that the antiviral spectra of action of certain nucleoside analogues may be significantly broadened by the application of suitable phosphate delivery motifs. Furthermore, we note a caveat on the recent observation that esterase-mediated hydrolysis to free amino acyl phosphoramidates may correlate with antiviral potency. It may be that such esterase lability is a necessary, but not a sufficient, test for activity.
